FBRX
NASDAQForte Biosciences
$36.70
+16.12 (+78.33%)
2026-07-09 00:00
Healthcare
Biotechnology
--
--
Short Interest (1 Year)
% of Volume Sold ShortMarket Cap
$430.7M
P/E Ratio
N/A
52W Low
52W High
$10.30
$37.58
Volume
4.8M
Analyst Rating
Hold
Target: $60
11 Analyst Ratings
Strong Buy
0
Buy
0
Hold
11
Sell
0
Price Target Range
Low: $52
Avg: $60
High: $64
About Forte Biosciences
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as celiac disease, vitiligo, alopecia areata, and type 1 diabetes. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
Employees
22
Website
fortebiorx.com
Financial Highlights
Annual
Quarterly
| Year | Revenue | Op Margin | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2025 | N/A | N/A% | -$69.4M | -$50.8M |
| 2024 | N/A | N/A% | -$35.5M | -$30.7M |
| 2023 | N/A | N/A% | -$31.5M | -$28.6M |
| 2022 | N/A | N/A% | -$13.9M | -$8.2M |
| 2021 | N/A | N/A% | -$21.7M | -$16.6M |
| 2026 Q1 | N/A | N/A% | -$22.1M | -$18.8M |
| 2025 Q4 | N/A | N/A% | -$24.8M | -$16.5M |
| 2025 Q3 | N/A | N/A% | -$17.7M | -$13.9M |
| 2025 Q2 | N/A | N/A% | -$11.2M | -$10.1M |
| 2025 Q1 | N/A | N/A% | -$15.7M | -$10.3M |
| 2024 Q4 | $38K | -19344.7% | -$7.2M | -$10.0M |
| 2024 Q3 | N/A | N/A% | -$8.4M | -$8.1M |
| 2024 Q2 | N/A | N/A% | -$12.5M | -$5.9M |